Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CD19 CAR-T (LV009) in Relapsed/Refractory CD19+ Non-Hodgkin's Lymphoma
NCT04237428Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- May 2019
- Primary completion
- Jun 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LV009 in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by PersonGen BioTherapeutics. Primary endpoint: Best Overall Response Rate at 6 months. Status: unknown.
02
Drugs
LV009
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04237428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04237428.